MedTrace Logo

Phase II Study of ASP3550 in Patients With Prostate Cancer

NCT00568516 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 273

Last updated 2014-10-29

No results posted yet for this study

Summary

To assess the effect of ASP3550 on the maintenance of serum testosterone suppression in patients with prostate cancer

Conditions

  • Prostatic Neoplasms

Interventions

DRUG

ASP3550

subcutaneous administration

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Central Contact · Astellas Pharma Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-10-31
Completion
2009-10-31

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00568516 on ClinicalTrials.gov